- Jun 30, 2021
NCT04770402: Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
NCT04770402: Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients NCT04770402: Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients This randomized, controlled trial is designed to evaluate the effect of acupuncture on Chemotherapy-Induced Peripheral Neuropathy (CIPN), other symptoms, and potential opioid and concomitant medication sparing effects in comparison to standard of care management in Multiple Myeloma subjects.
28
- Jun 30, 2021
NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab
IFM 2020-02 MInimal Residual Disease Adapted Strategy (MIDAS) Isa-KRd NCT04934475: Phase 3 - IFM 2020-02 -MInimal Residual Disease Adapted Strategy (MIDAS) - KRD-Isatuximab IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard v
566
- Jun 28, 2021
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM).
128
- Jun 27, 2021
THE MMRF - Multiple Myeloma Immunotherapy
THE MMRF - Multiple Myeloma Immunotherapy THE MMRF - Multiple Myeloma Immunotherapy Click here to read Learn more: Multiple Myeloma Research Foundation Education Programs https://themmrf.org Download the MMRF Patient Toolkit English and Spanish https://themmrf.org/resources/education-programs/
95
- Jun 26, 2021
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
PRISM High Risk Smoldering Multiple Myeloma NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM) The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma. The names of the study drugs involved in this study are: Daratumumab (also called Darzalex
139
- Jun 26, 2021
What are the different stages of Multiple Myeloma? REVISED - INTERNATIONAL STAGING SYSTEM (R-ISS)
IMWG Revised International Staging System Multiple Myeloma REVISED - INTERNATIONAL STAGING SYSTEM is based on blood work results and cytogenetic analysis from bone marrow. Oncologist formulate treatment plan based on stage of Myeloma along with other factors. REVISED - INTERNATIONAL STAGING SYSTEM (R-ISS) R-ISS STAGE 1: Serum beta-2 microglobulin <3.5 mg/L, Serum albumin ≥3.5 g/d Normal LDH standard-risk chromosomal abnormalities by FISH ( No del(17p), t(4;14), or t(14;16) by
287
- Jun 26, 2021
NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research
NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research An example of CART Cell therapy approved by FDA to treat relapsed & refractory Multiple Myeloma is Idecabtagene Vicleucel ( Abecma) Clinical trials with Abecma
238
- Jun 25, 2021
Multiple Myeloma Research Foundation - MMRF - Genomics
Multiple Myeloma Research Foundation - MMRF - Genomics | High Impact Topic (HIT) Genomics: Hear how doctors can use genomic information from your myeloma cells to provide therapy that is tailored to your myeloma subtype. Multiple Myeloma Research Foundation - MMRF - Genomics | High Impact Topic (HIT) Learn more: MMRF Resources https://themmrf.org/multiple-myeloma/resources/ Multiple Myeloma Research Foundation https://themmrf.org Multiple Myeloma Research Foundation - MMRF Vi
117
- Jun 25, 2021
NCT04751877: Phase 3 - Isa-Rd +/- Bortezomib Non Frail NTE Myeloma Elderly Patients IFM2020-05
(IFM 2020-05) BENEFIT IFM 2020-05 Study of Isatuximab+Lenalidomide+Dexamethasone With/Without Bortezomib in de Novo Non Frail NTE Multiple Myeloma Elderly Patients (IFM2020-05) The association lenalidomide and dexamethasone (Rd) has significantly improved the easiness of treating the NTE population and all drugs seem to be possible to combine to Rd. In that extent, proteasome inhibitors have always been one of the most impactful family of agents in MM, and as expected Bortezo
265
- Jun 25, 2021
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 05/08/2021, Dana-Farber Cancer Institute
MCRT Webcast - Myeloma Crowd Round Table, May 8, 2021 Dana-Farber Cancer Institute Myeloma Crowd Round Tables program Treating Myeloma at the Dana-Farber Cancer Institute | MCRT May 8, 2021 Round Table Audience Q&A | MCRT May 8, 2021 Learn more: MCRT Webcast - Myeloma Crowd Round Tables program Myeloma Crowd by HealthTree Upcoming Events https://www.myelomacrowd.org/myeloma/community Myeloma Crowd by HealthTree - YouTube
57
- Jun 25, 2021
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)
REST NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST) Newly diagnosed multiple myeloma patients ineligible for HD-ASCT will be included in the study. All participants will receive isatuximab in combination with bortezomib, lenalidomide and minimal dexamethasone until disease progression. The primary objective of this study is the MRD negativity rate during and/or after first 18 cycles of study treatment. Sponsor Oslo University Hospital Colla
72
- Jun 24, 2021
NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd
ClaSPd NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (ClaSPd) NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (ClaSPd) The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromyc
58
- Jun 24, 2021
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients This is a multicenter, open label clinical trial evaluating the safety of the combination of belantamab mafodotin + the combination treatment VRd (bortezomib, lenalidomide, dexamethasone) in newly diagnosed (ND) transplant eligible multiple myeloma (MM) patients.
46
- Jun 24, 2021
Multiple Myeloma Research Foundation - MMRF - Clinical Trials
Clinical Trials: Discover how clinical trials work. Multiple Myeloma Research Foundation - MMRF - Clinical Trials | High Impact Topic (HIT) Learn more: MMRF Resources https://themmrf.org/multiple-myeloma/resources/ Multiple Myeloma Research Foundation https://themmrf.org Multiple Myeloma Research Foundation - MMRF Videos Watch on YouTube
66
- Jun 24, 2021
NCT04937777: EMN 23 - Study on the Management & Outcome of Systemic AL Amyloidosis in Europe
EMN 23 NCT04937777: A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe NCT04937777: A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe This is a retrospective, observational, multicenter study to collect Real-World Evidence (RWE) data on systemic AL-AMY patients in Europe. Data from paper/electronic medical records and/or electronic databases from key reference centers in Europe will be used. Data wil
14
- Jun 24, 2021
What is the MMRF CureCloud®? Welcome to the MMRF CureCloud! Multiple Myeloma Research Foundation
What is the MMRF CureCloud®? Welcome to the MMRF CureCloud! Multiple Myeloma Research Foundation - MMRF The MMRF CureCloud® is a breakthrough, first-of-its-kind research study that includes free, at-home genomic testing aimed at informing smarter treatment plans and accelerating precision medicine for all myeloma patients. CureCloud participants will have access to a free state-of-the-art liquid biopsy genomic test, a free report on genetic variations in their multiple myelom
184
- Jun 24, 2021
American Cancer Society - www.cancer.org: What is CART Cell Therapy?
American Cancer Society - www.cancer.org: What is CART Cell Therapy? CAR T-cell therapy Learn more: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy CAR T-cell Therapy and Its Side Effects Learn more: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html
560
- Jun 23, 2021
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients This is a single arm, open label, single-center prospective study to evaluate the safety and efficacy of GC012F as frontline therapy for transplant eligible multiple myeloma(MM) patients with high-risk profile. Patients enrolled will be newly diagnosed treatment naïve patients who are eligible for transplant. Sponsor Sha
196
- Jun 23, 2021
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 04/24/2021
MCRT Webcast - Myeloma Crowd Round Table Myeloma Crowd Round Tables program MCRT Webcast Apr 24, 2021 The Role of Venetoclax in Myeloma - Jonathan Kaufman, MD | Novel Myeloma Therapies: Melphalan Flufenamide - Peter Voorhees, MD CAR-T Cell Therapy for Multiple Myeloma - Michaela Liedtke, MD Round Table Audience Q&A The Role of Venetoclax in Myeloma - Jonathan Kaufman, MD | MCRT Webcast Apr 24, 2021 Novel Myeloma Therapies: Melphalan Flufenamide - Peter Voorhees, MD | MCRT Web
51